UroGen Pharma (URGN) option IV into data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal optimism; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
UroGen Pharma (URGN) PT Raised to $53.50 at Ladenburg Thalmann
June 14, 2024 6:54 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on UroGen Pharma (NASDAQ: URGN) to $53.50 (from $48.00) while maintaining a Buy rating.
The analyst comments "UroGen disclosed strong ENVISION 12-month DoR data (82.3%) at an investor event on June 13, 2024; Rolling NDA submission expected to complete by September 2024; Potential approval as soon as 1Q25, with priority... More
Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
June 14, 2024 5:11 AM EDTGoldman Sachs analyst Paul Choi reiterated a Neutral rating and $22.00 price target on UroGen Pharma (NASDAQ: URGN).
The analyst comments "Encouraging data for UGN-102 far exceeded expectations on 12-month durability of response; focus shifting to regulatory filing and subsequent launch execution. URGN is outperforming today (+41%... More
